- Home
- BMBL vs ALT Comparison
BMBL vs ALT Comparison
Compare BMBL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | ALT |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 415.3M |
| IPO Year | 2021 | 2005 |
Fundamental Metrics
Financial Performance| Metric | BMBL | ALT |
|---|---|---|
| Price | $3.05 | $3.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 5 |
| Target Price | $4.65 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 2.9M | 2.8M |
| Earning Date | 01-01-0001 | 06-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,071,643,000.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $756,308.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 1.88 | ★ 105.00 |
| 52 Week Low | $2.61 | $2.91 |
| 52 Week High | $8.63 | $7.73 |
Technical Indicators
Market Signals| Indicator | BMBL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.78 | 31.55 |
| Support Level | $2.61 | $3.39 |
| Resistance Level | $3.85 | $4.25 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 71.54 | 15.24 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.